FEINSTEIN is a pharmaceutical company focused on Neurology, Oncology. Key products include FLUORODOPA F18.
FEINSTEIN's Key Drugs
FEINSTEIN's core commercial portfolio centers on FLUORODOPA F18, spanning Neurology and Oncology — its most strategically important drugs approved in the last 15 years.
FEINSTEIN's Recent FDA Approvals
New NDA/BLA approvals for FEINSTEIN over the last two years — novel drugs only, excluding generics and label supplements.
FEINSTEIN's Therapeutic Areas
FEINSTEIN's approved drugs and pipeline span 2 therapeutic areas, led by Neurology and Oncology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
FEINSTEIN's Top Competitors
FEINSTEIN's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
FEINSTEIN Pipeline Snapshot
Active clinical trials for FEINSTEIN across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • FLUORODOPA F18 leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2005-08-19
- Latest
- 2023-11-09
- Applications
- 3